aav5-rpgr
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Mar 16, 2021 (NCT04794101)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- X-linked retinitis pigmentosa GTPase regulatorSupplementation
supplementation - rpgr
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04671433 | Phase 3 | Mar 16, 2021 | Janssen Pharmaceutica NV, MeiraGTx |
| NCT04794101 | Phase 3 | Mar 16, 2021 | Janssen Pharmaceutica NV, MeiraGTx |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 2 | 0 | 1 | 2021 |
| MeiraGTx | For profit | 2 | 2 | 1 | 2021 |
2 organizations
Page 1 / 1